SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma’s arm acquires Neviton Softech

17 Feb 2026 Evaluate

Strides Pharma Science’s wholly owned subsidiary -- Arco Lab has completed the acquisition of Neviton Softech (Neviton). Neviton is engaged in providing IT services and engineering solutions to a diverse range of businesses. Neviton’s core expertise includes developing machine interfaces through IoT devices and integrating live data feeds into real time applications. Arco Lab had previously acquired a 25% equity stake in Neviton in August 2022, followed by an additional 25% stake in January 2024. Pursuant to the current transaction, Arco Lab has acquired the remaining 50% equity interest in Neviton. Subsequently, the Neviton has become a wholly owned subsidiary of Arco Lab and step-down subsidiary of the company with effect from February 16, 2026. The 50% stake in Neviton has been acquired for a consideration of 2 million euros or around Rs 21.77 crore.

Arco Lab was established to provide best-in-class business services in driving business and IT transformation, cost efficiencies and operational excellence and serve as a Global Life Science Capability Centre. Arco Lab also provides IT Infrastructure services, Enterprise Application Services, Manufacturing IT Services, New Technologies and Cybersecurity services. With the investment, Neviton and Arco Lab synergize their strengths and enables Arco Lab to offer better knowledge-based and IT services ensuring higher scale, scope and significant cash savings and enable better internal group wise digitization process. Accordingly, Neviton’s acquisition is complementary to Arco Lab’s business objectives.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

997.65 1.75 (0.18%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×